Makani Julie, Masamu Upendo, Tluway Furahini, Sangeda Raphael Z, Soka Deogratius, Osati Elisha, Kindole Christine, Cox Sharon E, Mgaya Josephine, Shayo Sigfrid C, Makubi Abel, Balandya Emmanuel, Mmbando Bruno P
Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.
Muhimbili Sickle Cell Programme, Muhimbili University of Health and Allied Sciences, Tanzania.
EClinicalMedicine. 2024 Oct 3;76:102839. doi: 10.1016/j.eclinm.2024.102839. eCollection 2024 Oct.
Anaemia in sickle cell disease (SCD) is a significant cause of morbidity and mortality, but few studies have reported on the burden and outcome of very severe anaemia. This study described the epidemiology of very severe anaemia by determining the prevalence and incidence, investigating associated clinical and laboratory factors, and assessing outcomes in SCD.
A 10-year prospective cohort study involving SCD patients of all ages was conducted at Muhimbili National Hospital in Tanzania between 2004 and 2013. SCD included Homozygous SS-Sickle cell anaemia and Sβ thalassemia at clinics and during hospitalization visits. Very severe anaemia was defined as Haemoglobin <5 g/dL at steady-state which was a period when a patient was stable with no blood transfusion in past 3 months or accute pain report in the previous month.
There were 28,293 (92.9%) clinic visits and 2158 hospitalisations amongst 3586 patients. Mean haemoglobin concentration at clinic was 7.4 g/dL, (95% CI: 7.4-7.5) compared to hospitalisation [6.4 g/dL, 95% CI: 6.3-6.5], p < 0.001. Prevalence of very severe anaemia at the clinic was 4.1%, and 23.8% during hospitalization, while the overall incidence was 114.1 (95% CI: 108.2-120.2) events per 1000 person years. Risk ratio of dying for patients with very severe anaemia was 4.78 times higher (95% CI: 3.65-6.25, p < 0.001) than in individuals without very severe anaemia. The risk ratio for mortality was highest in children aged <2 years, and was decreasing steadily with increase in age, from HR = 0.73 (95% CI: 0.39-1.35) in children aged 2-4 years to HR of 0.38 (95% CI: 0.20-0.71) in patients in age group 10-17 years when compared to those aged 0-1 years. Mortality risk ratio was higher (HR = 6.76 [95% CI: 4.31-10.62, p < 0.001]) in patients with steady-state haemoglobin <5 g/dL and presenting with very severe anaemia before death compared to those with steady state haemoglobin ≥5 g/dL and haemoglobin ≥5 g/dL before death.
The burden of very severe anaemia in SCD was high, especially during hospitalization, and was independent predictor of mortality. There is an urgent need to improve prevention, diagnosis, and interventions for very severe anaemia in SCD in Africa. More research to elucidate the aetiology and mechanisms of anaemia in this population is required.
Government of the United Republic of Tanzania, Wellcome Trust, United Kingdom (JKM 072064; Project grant 080025, Strategic award 084538).
镰状细胞病(SCD)中的贫血是发病和死亡的重要原因,但很少有研究报告极重度贫血的负担和结局。本研究通过确定患病率和发病率、调查相关临床和实验室因素以及评估SCD的结局,描述了极重度贫血的流行病学情况。
2004年至2013年期间,在坦桑尼亚的穆希姆比利国家医院对所有年龄段的SCD患者进行了一项为期10年的前瞻性队列研究。SCD包括纯合子SS-镰状细胞贫血和Sβ地中海贫血,在门诊和住院期间进行观察。极重度贫血定义为稳态时血红蛋白<5 g/dL,稳态是指患者在过去3个月内未输血且前一个月无急性疼痛报告的时期。
3586例患者中有28293次(92.9%)门诊就诊和2158次住院治疗。门诊时的平均血红蛋白浓度为7.4 g/dL(95%CI:7.4-7.5),而住院时为6.4 g/dL(95%CI:6.3-6.5),p<0.001。门诊时极重度贫血的患病率为4.1%,住院期间为23.8%,而总体发病率为每1000人年114.1例(95%CI:108.2-120.2)。极重度贫血患者的死亡风险比没有极重度贫血的个体高4.7倍(95%CI:3.65-6.25,p<0.001)。<2岁儿童的死亡风险比最高,并且随着年龄的增长而稳步下降,与0-1岁儿童相比,2-4岁儿童的HR=0.73(95%CI:0.39-1.35),10-17岁年龄组患者的HR为0.38(95%CI:0.20-0.71)。与死亡前稳态血红蛋白≥5 g/dL的患者相比,死亡前稳态血红蛋白<5 g/dL且患有极重度贫血的患者的死亡风险比更高(HR=6.76[95%CI:4.31-10.62,p<0.001])。
SCD中极重度贫血的负担很高,尤其是在住院期间,并且是死亡的独立预测因素。迫切需要改善非洲SCD中极重度贫血的预防、诊断和干预措施。需要更多的研究来阐明该人群贫血的病因和机制。
坦桑尼亚联合共和国政府、英国惠康信托基金会(JKM 072064;项目资助080025,战略奖084538)。